Lilly’s CEO keeps faith in the pipeline as biotech gets ‘too expensive’

Damian Garde

Eli Lilly is staking its future on a pair of high-stakes Phase III programs, shying away from any big buyouts as sticker prices continue to soar.

FierceBiotech News

Share This Post

Related Articles

Leave a Reply

© 2018 Global Regulatory Science. All rights reserved. Site Admin · Entries RSS · Comments RSS